drug · small molecule

VYALEV

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

targets

Aromatic-L-amino-acid decarboxylase

all catalysts(0)

nothing on the calendar yet

News(1)

AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago

brand

VYALEV

trade names

Foscarbidopa component of abbv-951, Foscarbidopa component of vyalev

generic

FOSCARBIDOPA

MOA

12.1 Mechanism of Action VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.

indication

1 INDICATIONS AND USAGE VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). VYALEV is a combination of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

VYALEV

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

targets

Aromatic-L-amino-acid decarboxylase

all catalysts(0)

nothing on the calendar yet

News(1)

AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago

brand

VYALEV

trade names

Foscarbidopa component of abbv-951, Foscarbidopa component of vyalev

generic

FOSCARBIDOPA

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

VYALEV

🐶 often sniffed alongside

targets

all catalysts(0)

News(1)

Report a data issue

comments(0)

VYALEV

🐶 often sniffed alongside

targets

all catalysts(0)

News(1)

Report a data issue

comments(0)